Killer cells add fire to fuel immunotherapy

Christopher J. Nicolai; David H Raulet

doi:10.1126/science.abc2502

Article2018

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Joy Hsu, Jonathan J. Hodgins, Malvika Marathe, Chris J. Nicolai, Marie‐Claude Bourgeois‐Daigneault, Troy N. Trevino, Camillia S. Azimi, Amit Scheer, Haley E. Randolph, Thornton W. Thompson, Lily Zhang, Alexandre Iannello, Nikhita Mathur, Karen Jardine, Georgia Kirn, John C. Bell, Michael W. McBurney, David H Raulet, Michele Ardolino

Article2021

Tumor-intrinsic determinants of immunogenic cell death modalities

Samuel T. Workenhe, Jonathan Pol, Guido Guido Kroemer

Article2025

Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates

Oliver Kepp, Guido Guido Kroemer

Article2022

Roles of natural killer cells in immunity to cancer, and applications to immunotherapy

Natalie K. Wolf, Djem Kissiov, David H Raulet

Article2010

Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists

Deepa Rajagopal, Carine Paturel, Yannis Morel, Satoshi Uematsu, Akira Shizuo, Sandra S. Diebold

Blood

Killer cells add fire to fuel immunotherapy

Abstract

Discussion(0)

Related publications

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Tumor-intrinsic determinants of immunogenic cell death modalities

Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates

Roles of natural killer cells in immunity to cancer, and applications to immunotherapy

Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists